An interventional study of Blood sample collection at surgery time and 12 months later in Congenital Heart Defects, Thymectomy and Immunological Deficiency Syndrome, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.
Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 68th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 0–18
Nantes University Hospital · Sites in France
Ages 0 min–36 mo
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 50
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only · Healthy volunteers
University Hospital, Bordeaux · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: Up to 6 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 91 across the 34 interventional studies, 300 across the 39 observational. Of the 39 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 73 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 5 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Defects, Congenital with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
| NCT07864129University Hospital, Strasbourg, FranceVolution of Pulmonary Artery Dimensions in Tetralogy of Fallot | 2027-04-18 |
| NCT06998290University Hospital, BordeauxFeasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life | 2027-06-01 |
| NCT06442592Nantes University HospitalCharacterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects | 2027-07-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 73 studies in Heart Defects, Congenital with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart surgery in infants typically involves complete removal of the thymus gland to improve access to the heart. However, the thymus plays a key role in developing the immune system in early childhood, especially in the production and maturation of T lymphocytes, which help the body defend itself against infections.
The THYMIC study tests the hypothesis that partial removal of the thymus (partial thymectomy) during heart surgery may better preserve the child's immune function compared to total removal (complete thymectomy). The goal is to determine whether this conservative surgical approach could reduce the risk of immune system impairment and infections in the months following surgery.
This is a prospective, interventional, single-center study conducted at CHU de Nantes, involving 3 groups of infants:
By comparing the immune responses and infection rates among the groups, the researchers hope to better understand the long-term effects of thymectomy in infants. The results could support future recommendations to preserve part of the thymus when possible during heart surgery.
Participation in the study does not change the medical or surgical care of the child. The decision to perform a partial or complete thymectomy is made by the surgeon based on the child's anatomy. The additional blood samples are small in volume and follow current safety regulations.
The THYMIC study is a prospective, single-center, interventional clinical trial conducted at the University Hospital of Nantes (CHU de Nantes), France. It aims to evaluate the medium-term immunological impact of thymectomy (total versus partial) in infants undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) before the age of 6 months.
Background and Rationale During most pediatric cardiac surgeries, the thymus is completely removed to allow better access to the heart and great vessels. However, the thymus plays a critical role in T-cell development during infancy, contributing to immune system maturation. Prior studies suggest that complete thymectomy in early life may result in persistent alterations in T-cell immunity and increased susceptibility to infections. Yet, the comparative impact of partial versus complete thymectomy on immune function remains poorly studied.
Partial thymectomy is technically feasible in selected cases depending on the anatomy, and could offer a balance between surgical access and immune preservation. The THYMIC study tests the hypothesis that partial thymectomy is associated with less impairment of cellular immunity at 12 months postoperatively and could therefore become the preferred surgical approach in appropriate cases.Study Design
This is a non-randomized, controlled study including 70 infants:
The THYMIC study is a prospective, single-center, interventional clinical trial conducted at the University Hospital of Nantes (CHU de Nantes), France. It aims to evaluate the medium-term immunological impact of thymectomy (total versus partial) in infants undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) before the age of 6 months.
Background and Rationale During most pediatric cardiac surgeries, the thymus is completely removed to allow better access to the heart and great vessels. However, the thymus plays a critical role in T-cell development during infancy, contributing to immune system maturation. Prior studies suggest that complete thymectomy in early life may result in persistent alterations in T-cell immunity and increased susceptibility to infections. Yet, the comparative impact of partial versus complete thymectomy on immune function remains poorly studied.
Partial thymectomy is technically feasible in selected cases depending on the anatomy, and could offer a balance between surgical access and immune preservation. The THYMIC study tests the hypothesis that partial thymectomy is associated with less impairment of cellular immunity at 12 months postoperatively and could therefore become the preferred surgical approach in appropriate cases.
Study Design
This is a non-randomized, controlled study including 70 infants:
The study involves two blood draws:
Parents are given a standardized infection monitoring questionnaire at hospital discharge, to be completed with their pediatrician or other care providers over the 12-month follow-up. A phone call is scheduled at 6 months to reinforce compliance. At 12 months, families return for the second blood draw and review of the infection questionnaire. An additional consultation is conducted 15 days later to provide results and arrange follow-up if needed.
Primary Objective To compare cellular immune profiles at 12 months between infants with partial versus complete thymectomy. Key markers include absolute counts of lymphocytes and subsets, and T-cell receptor excision circles (TRECs).
Secondary Objectives
To compare:
Methodology Notes Due to the impossibility of preoperative randomization (surgical decision on thymectomy extent depends on intraoperative anatomy), this is a non-randomized study with group allocation based on surgical findings.
All data are pseudonymized and collected in an electronic case report form (eCRF). Immunological assays are processed via the CHU's certified laboratories (CIMNA platform and hematology department).
Ethical Considerations and Risk-Benefit Assessment The study poses minimal risk. Blood samples are within safe volume limits for infants, and pain is minimized using anesthetic cream and inhaled analgesia (EMLA, MEOPA). Thymectomy extent is based solely on clinical indication and does not depend on study participation. Families benefit from enhanced immunological monitoring, which could identify and help manage acquired immune deficiencies.
Significance This study may provide critical data to support a shift toward more conservative surgical practices regarding thymus preservation in early cardiac surgery, with the potential to reduce long-term immunological sequelae in this vulnerable population.
Inclusion Criteria:
For the control groups:
Control group A (cardiac surgery without thymectomy):
Control group B (non-cardiac surgery)
Exclusion Criteria :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB), during which a complete thymectomy is performed for surgical access to the heart and great vessels. The extent of thymus resection is determined by the cardiac surgeon intraoperatively, based on anatomical considerations
Diagnostic Test: Blood sample collection at surgery time and 12 months later
Infants undergoing cardiac surgery with CPB, during which a partial thymectomy is performed, with an effort to preserve thymic tissue when anatomically feasible.
Diagnostic Test: Blood sample collection at surgery time and 12 months later
Infants undergoing: * Cardiac surgery by thoracotomy without thymectomy (e.g., for aortic coarctation) or * Non-cardiac surgery (e.g., digestive procedures) with complete preservation of the thymus. These patients serve as immunological reference controls
Diagnostic Test: Blood sample collection at surgery time and 12 months later
each participant undergoes a blood test 1) at surgery time and 2) 12 months after surgery. These 5mL samples include: * Blood cell count * TREC dosage * Complete Lymphocytes immunophenotyping * Immunoglobulin dosage
T-Lymphocyte response
biological endpoint with absolute quantification of LyTs, LyT subpopulations and TRECs.
Time frame: 12 months after surgery
Humoral response
absolute quantification of LyB, weighted immunoglobulin assays and post-vaccination serologies
Time frame: 12 months after surgery
Clinical impact
the number of infectious episodes, their severity as assessed by the need for hospitalisation, the number of days spent in intensive care, the number of days on antibiotics, etc.
Time frame: 12 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 28 months is below that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.